Oncotelic Therapeutics, Inc. (OTLC) Net income 2017–2026
Oncotelic Therapeutics, Inc. (OTLC) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
$249.3MFY2026 · since FY2017: -$13.7M → $249.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | $249.3M | +5610.7% |
| FY2025 | -$4.5M | +42.8% |
| FY2024 | -$7.9M | -255.1% |
| FY2023 | $5.1M | +154.3% |
| FY2022 | -$9.4M | +1.2% |
| FY2021 | -$9.5M | -43.2% |
| FY2020 | -$6.6M | -831.3% |
| FY2019 | -$712,738 | +94.8% |
| FY2018 | -$13.8M | -1.2% |
| FY2017 | -$13.7M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More OTLC financial trends
OTLC RevenueOTLC Net marginOTLC Gross profitOTLC Gross marginOTLC Operating incomeOTLC Operating marginOTLC Operating cash flowOTLC Free cash flowOTLC Capital expendituresOTLC Return on equityOTLC Stock buybacksOTLC Dividends paidOTLC Total assetsOTLC Total liabilitiesOTLC Shareholders’ equityOTLC overview →